Skip to main content

Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.

Publication ,  Journal Article
Ross, JS; Ginsburg, GS
Published in: Expert Rev Mol Diagn
November 2002

The Introduction of targeted therapeutics into clinical practice has created major opportunities for further development of the molecular diagnostics industry. Emerging genomic and proteomic technologies and information are now resulting in the molecular subclassification of disease as the basis for diagnosis, prognosis and therapeutic selection. The ultimate goals of personalized medicine are to take advantage of a molecular understanding of disease, both to optimize drug development and direct preventive resources and therapeutic agents at the right population of people while they are still well. Single nucleotide polymorphisms identification and genotyping have uncovered predisposition markers from cancer and heart disease as well in the prediction of both drug efficacy and toxicity. Pharmacogenomic and pharmacodynamic assays are being developed to enhance the speed and decrease the cost of drug development, as well as reduce side effects and increase response rates in a variety of diseases. The traditional trial and error practice of medicine is progressively eroding in favor of more precise marker-assisted diagnosis and safer and more effective molecularly guided treatment of disease. For the diagnostics industry this represents an unprecedented opportunity for integration, increased value and commercial opportunities for molecularly-derived tests.

Duke Scholars

Published In

Expert Rev Mol Diagn

DOI

ISSN

1473-7159

Publication Date

November 2002

Volume

2

Issue

6

Start / End Page

531 / 541

Location

England

Related Subject Headings

  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • Oligonucleotide Array Sequence Analysis
  • Neoplastic Syndromes, Hereditary
  • Molecular Diagnostic Techniques
  • Humans
  • Genetic Predisposition to Disease
  • Genes, Tumor Suppressor
  • Gene Expression Profiling
  • Forecasting
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ross, J. S., & Ginsburg, G. S. (2002). Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. Expert Rev Mol Diagn, 2(6), 531–541. https://doi.org/10.1586/14737159.2.6.531
Ross, Jeffrey S., and Geoffrey S. Ginsburg. “Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.Expert Rev Mol Diagn 2, no. 6 (November 2002): 531–41. https://doi.org/10.1586/14737159.2.6.531.
Ross, Jeffrey S., and Geoffrey S. Ginsburg. “Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.Expert Rev Mol Diagn, vol. 2, no. 6, Nov. 2002, pp. 531–41. Pubmed, doi:10.1586/14737159.2.6.531.

Published In

Expert Rev Mol Diagn

DOI

ISSN

1473-7159

Publication Date

November 2002

Volume

2

Issue

6

Start / End Page

531 / 541

Location

England

Related Subject Headings

  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • Oligonucleotide Array Sequence Analysis
  • Neoplastic Syndromes, Hereditary
  • Molecular Diagnostic Techniques
  • Humans
  • Genetic Predisposition to Disease
  • Genes, Tumor Suppressor
  • Gene Expression Profiling
  • Forecasting